Ona Therapeutics advances as a clinical-stage company and appoints Aleix Prat, MD, PhD, as Chief Medical Officer

/in

More than half of the patients planned for the clinical study have already been enrolled, with the trial progressing rapidly through dose escalation Advancement of ONA-255 marks an important milestone following Ona’s $86.6 million Series B financing Internationally recognized oncologist and physician-scientist Aleix Prat, MD, PhD, appointed Chief Medical Officer, as Jutta Amersdorffer, MD, MBA, […]

Read more

Breye Therapeutics has a paper on its oral danegaptide treatment for patients with NPDR published in Science Translational Medicine

/in

Oral treatment danegaptide represents “a potential paradigm shift” toward earlier, non-invasive treatment of Non-Proliferative Diabetic Retinopathy (NPDR), say authors Study “provides compelling evidence” that danegaptide robustly protects inner blood-retina barrier (iBRB), while also dampening VEGF-associated activity This “dual approach”, and its ability to be used earlier, “may translate into improved outcomes” Breye is now planning […]

Read more

AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104

/in

All primary endpoints of the study were met, with ACI-7104 shown to be generally safe and well tolerated Strong immunogenicity demonstrated, with 100% response rate after three immunizations Clear antibody penetration into the cerebrospinal fluid (CSF) and signals for target engagement Discussions with FDA regarding future development path planned for early 2027 AC Immune to […]

Read more

Anaconda Biomed Secures $56 Million Financing from New and Existing Investors

/in

Proceeds used to complete ongoing ATHENA pivotal IDE study, continue product development, and secure global regulatory approvals for neurovascular portfolio   BARCELONA, Spain and MARIN, Calif. – September 23, 2026 – Anaconda Biomed, a medical technology company developing a next-generation portfolio of novel thrombectomy catheters based on its core funnel catheter technology platform, today announced […]

Read more

AstronauTx awarded research funding from The Michael J. Fox Foundation and Parkinson’s UK to explore sleep-based approaches for Parkinson’s disease

/in

MJFF grant will support development of a potential disease-modifying treatment for prodromal Parkinson’s disease by targeting restorative sleep mechanisms Parkinson’s UK-funded research with University College London (UCL) will further explore the link between enhanced slow-wave sleep and glymphatic flow, the brain’s natural waste-clearance mechanism London, UK, 22 September 2026 – AstronauTx Ltd (“AstronauTx”), a biotechnology […]

Read more
© Optimum Strategic Communications.